Patent classifications
C12Y203/01005
NITRATED PSILOCYBIN DERIVATIVES AND METHODS OF USING
Disclosed are novel nitrated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The nitrated psilocybin derivative compounds may be chemically synthesized or biochemically synthesized in host cells.
PRENYLATED PSILOCYBIN DERIVATIVES AND METHODS OF USING
Disclosed are novel prenylated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced in vitro or in vivo using a biosynthetic system which comprises cells comprising a prenyl transferase, and, optionally, additional enzymes, including a decarboxylase, and an N-acetyl transferase.
MICROORGANISM FOR PRODUCING PUTRESCINE AND PROCESS FOR PRODUCING PUTRESCINE BY USING SAME
The present invention relates to a microorganism for producing putrescine and a method for producing putrescine by using same.
METHODS AND COMPOSITIONS FOR INHIBITING NECROPTOSIS IN NEUROVASCULAR AND/OR NEURODEGENERATIVE DISEASES OR DISORDERS
The present disclosure provides agents, compositions, and methods for inhibiting necroptosis in the brains of subjects in need thereof. In some embodiments, agents, compositions, and methods provided herein are useful for treating necroptosis-mediated neurovascular or neurodegenerative diseases or disorders, e.g., Alzheimer's disease.
Prenylated psilocybin derivatives and methods of using
Disclosed are novel prenylated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced in vitro or in vivo using a biosynthetic system which comprises cells comprising a prenyl transferase, and, optionally, additional enzymes, including a decarboxylase, and an N-acetyl transferase.
Cell-based production of nonulosonates
The present invention relates to the cell-based production of bacterial nonulosonates and their biosynthetic precursors. Specifically, the present invention provides recombinant cells for the production of pseudaminic acid, legionaminic acid, UDP-2,4-diacetamido-2,4,6-trideoxy--L-altropyranose, and UDP-2,4-diacetamido-2,4,6-trideoxy--D-glucopyranose. Methods for producing the sugars are also provided.
RECOMBINANT MICROORGANISM HAVING DIAMINE PRODUCING ABILITY AND METHOD FOR MANUFACTURING DIAMINE
[Problem of invention] To provide a recombinant microorganism and a method for manufacturing a diamine that realize at least one of a simplified process and a reduction in effluent treatment cost in production of a diamine, and to provide a halophilic and/or alkalophilic recombinant microorganism having suppressed N-acetyldiamine production.
[Solution of problem] A halophilic and/or alkalophilic recombinant microorganism having a diamine producing ability, in which the diamine is represented by formula NH.sub.2CH.sub.2(CH.sub.2).sub.nCH.sub.2NH.sub.2 (in the formula, n is an integer of 0 to 10), and the recombinant microorganism resulting from modification of a halophilic and/or alkalophilic host microorganism so as to impart a diamine producing ability; and a halophilic and/or alkalophilic recombinant microorganism having a diamine producing ability, the recombinant microorganism containing one or more genetic modifications that suppress an N-acetylation enzyme that N-acetylates a diamine compound to produce an N-acetyldiamine compound.
Cell-Based Production of Nonulosonates
The present invention relates to the cell-based production of bacterial nonulosonates and their biosynthetic precursors. Specifically, the present invention provides recombinant cells for the production of pseudaminic acid, legionaminic acid, UDP-2,4-diacetamido-2,4,6-trideoxy--L-altropyranose, and UDP-2,4-diacetamido-2,4,6-trideoxy--D-glucopyranose. Methods for producing the sugars are also provided.